NYSEAMERICAN:CRMD - CorMedix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2799 +0.01 (+3.71 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$0.2799
Today's Range$0.2707 - $0.2995
52-Week Range$0.17 - $0.77
Volume1.18 million shs
Average Volume1.54 million shs
Market Capitalization$18.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.6
CorMedix logoCorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16,300.49%
Return on Equity-318.95%
Return on Assets-227.65%

Miscellaneous

EmployeesN/A
Outstanding Shares81,900,000
Market Cap$18.50

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biotechnology company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.12 million. CorMedix had a negative net margin of 16,300.49% and a negative return on equity of 318.95%. View CorMedix's Earnings History.

When is CorMedix's next earnings date?

CorMedix is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for CorMedix.

What price target have analysts set for CRMD?

2 equities research analysts have issued 1-year price objectives for CorMedix's stock. Their predictions range from $2.00 to $3.00. On average, they anticipate CorMedix's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 793.2% from the stock's current price. View Analyst Ratings for CorMedix.

What is the consensus analysts' recommendation for CorMedix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting CorMedix?

CorMedix saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 6,805,612 shares, a decrease of 5.3% from the June 15th total of 7,183,258 shares. Based on an average trading volume of 1,618,517 shares, the short-interest ratio is presently 4.2 days. Approximately 8.8% of the shares of the stock are short sold. View CorMedix's Current Options Chain.

Who are some of CorMedix's key competitors?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:
  • Mr. Khoso Baluch, CEO & Director (Age 60)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 62)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations
  • Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance

Has CorMedix been receiving favorable news coverage?

News articles about CRMD stock have trended somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CorMedix earned a media sentiment score of 0.07 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $0.2799.

How big of a company is CorMedix?

CorMedix has a market capitalization of $18.50 million.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.


MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.